Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing.
The complement (C) system has previously been implicated in several diseases of muscle. We here report that human myoblasts or rhabdomyosarcoma cell lines spontaneously activate C through the classical pathway, causing release of anaphylatoxins and coating of myoblasts with opsonic C fragments but without causing cell killing. Survival of myoblasts is a consequence of the abundant expression of the membrane C regulatory molecules MCP and CD59, and neutralization of CD59 renders cells susceptible to C killing. The decay-accelerating factor was expressed at a very low level. Myoblasts and rhabdomyosarcoma lines also abundantly express the fluid-phase regulators C1-inhibitor, factor H, C4 binding protein, S-protein, and clusterin and secrete a soluble form of CD59. Expression of membrane and fluid-phase regulators is enhanced by either IFN-gamma or TNF-alpha. Although myoblasts resist C killing, spontaneous activation of C on these cells may have important consequences in inflammatory diseases of muscle where the generation of anaphylactic and opsonic fragments will recruit and activate inflammatory cells. C activation on myoblasts may also have consequences for the use of these cells as vehicles for gene delivery. Inhibition of C using soluble complement receptor I (sCR1) efficiently protected myoblasts from C attack in vitro, and this agent, already being tested in therapy of several C-mediated diseases, might be of value in inflammatory muscle disease and in improving the efficiency of gene delivery.
Gasque
P
P
Department of Medical Biochemistry, University of Wales College of Medicine, Cardiff, United Kingdom.
Morgan
B P
BP
Legoedec
J
J
Chan
P
P
Fontaine
M
M
D016923:Cell Death / Q000276:immunology; D002478:Cells, Cultured; D003169:Complement Inactivator Proteins / Q000096:biosynthesis / Q000235:genetics; D003171:Complement Pathway, Classical / Q000235:genetics*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D018482:Muscle, Skeletal / Q000166:cytology* / Q000276:immunology* / Q000378:metabolism; D012333:RNA, Messenger / Q000302:isolation & purification; D017463:Receptors, Complement 3b / Q000235:genetics / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology; D012208:Rhabdomyosarcoma / Q000235:genetics / Q000276:immunology; D012995:Solubility; D014407:Tumor Cells, Cultured
D003169:Complement Inactivator Proteins; D012333:RNA, Messenger; D017463:Receptors, Complement 3b; D011994:Recombinant Proteins